- Home
- STTK vs KLTR Comparison
STTK vs KLTR Comparison
Compare STTK & KLTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- KLTR
- Stock Information
- Founded
- STTK 2016
- KLTR 2006
- Country
- STTK United States
- KLTR United States
- Employees
- STTK N/A
- KLTR N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- KLTR EDP Services
- Sector
- STTK Health Care
- KLTR Technology
- Exchange
- STTK Nasdaq
- KLTR Nasdaq
- Market Cap
- STTK 37.6M
- KLTR 302.6M
- IPO Year
- STTK 2020
- KLTR 2021
- Fundamental
- Price
- STTK $0.83
- KLTR $1.99
- Analyst Decision
- STTK Hold
- KLTR Buy
- Analyst Count
- STTK 4
- KLTR 3
- Target Price
- STTK $3.00
- KLTR $2.83
- AVG Volume (30 Days)
- STTK 401.8K
- KLTR 369.0K
- Earning Date
- STTK 07-31-2025
- KLTR 08-07-2025
- Dividend Yield
- STTK N/A
- KLTR N/A
- EPS Growth
- STTK N/A
- KLTR N/A
- EPS
- STTK N/A
- KLTR N/A
- Revenue
- STTK $4,606,000.00
- KLTR $180,920,000.00
- Revenue This Year
- STTK N/A
- KLTR $3.46
- Revenue Next Year
- STTK N/A
- KLTR $3.67
- P/E Ratio
- STTK N/A
- KLTR N/A
- Revenue Growth
- STTK 69.65
- KLTR 2.40
- 52 Week Low
- STTK $0.69
- KLTR $1.06
- 52 Week High
- STTK $4.99
- KLTR $2.82
- Technical
- Relative Strength Index (RSI)
- STTK 39.19
- KLTR 44.51
- Support Level
- STTK $0.77
- KLTR $1.92
- Resistance Level
- STTK $0.91
- KLTR $2.06
- Average True Range (ATR)
- STTK 0.08
- KLTR 0.11
- MACD
- STTK -0.02
- KLTR -0.00
- Stochastic Oscillator
- STTK 16.23
- KLTR 49.06
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About KLTR Kaltura Inc.
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.